XGN

Exagen Inc

8.59

Oct 30 • 3:59 PM ET -0.11 (-1.26%)

8.55

Aftermarket • 7:30 PM ET -0.04 (-0.47%)

Healthcare Diagnostics & Research USA Micro NASD

Peers: BDSX CSTL MYGN MDXH FLGT VCYT CDNA DGX NEO QTRX

| Held by: VTI VXF IWC BUSM QQQS

Scroll to Statements

Index	-
Market Cap	208.10M
Enterprise Value	211.17M
Income	-18.92M
Sales	71.12M
Book/sh	0.50
Cash/sh	1.02
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	216
IPO	Sep 19, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	2.93
P/B	17.01
P/C	8.46
P/FCF	-
EV/EBITDA	-
EV/Sales	2.97
Quick Ratio	2.88
Current Ratio	3.18
Debt/Eq	2.26
LT Debt/Eq	2.05
Option/Short	Yes / Yes

EPS (ttm)	-0.81
EPS next Y	-0.50
EPS next Q	-0.18
EPS this Y	29.71%
EPS next Y	23.68%
EPS next 5Y	28.97%
EPS past 3/5Y	30.65% 6.84%
Sales past 3/5Y	13.47% 9.66%
EPS Y/Y TTM	9.70%
Sales Y/Y TTM	20.83%
EPS Q/Q	37.15%
Sales Q/Q	15.92%
Earnings	Nov 10 BMO
EPS/Sales Surpr.	32.08% 12.03%

Insider Own	40.57%
Insider Trans	-0.41%
Inst Own	36.54%
Inst Trans	-10.00%
ROA	-34.19%
ROE	-113.82%
ROIC	-50.75%
Gross Margin	58.64%
Oper. Margin	-18.58%
Profit Margin	-26.61%
SMA20	6.46%
SMA50	8.44%
SMA200	70.91%
Trades

Shs Outstand	24.19M
Shs Float	14.40M
Short Float	4.68%
Short Ratio	1.86
Short Interest	0.67M
52W High	11.92 -27.94%
52W Low	2.59 231.66%
Volatility	6.68% 6.99%
ATR (14)	0.52
RSI (14)	58.62
Beta	2.27
Rel Volume	1.09
Avg Volume	361.82K
Volume	394,020

Perf Week	18.16%
Perf Month	8.87%
Perf Quarter	83.55%
Perf Half Y	180.72%
Perf YTD	41.28%
Perf Year	-26.96%
Perf 3Y	432.88%
Perf 5Y	-26.08%
Perf 10Y	-
Recom	1.00
Target Price	10.57
Prev Close	8.70
Price	8.59
Change %	-1.26%

Consensus

Strong Buy

Avg. Price Target

$10.57

Implied Upside

+23.1%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 11, 2026	Resumed	RB. Riley Securities	Buy	$12	+39.7%
Jun 25, 2026	Initiated	RRoth Capital	Buy	$8	-6.9%
Sep 11, 2025	Initiated	RB. Riley Securities	Buy	$15	+74.6%
Jul 30, 2025	Upgrade	KKeyBanc Capital Markets	Sector Weight → Overweight	$12	+39.7%
Jul 23, 2025	Initiated	CCraig Hallum	Buy	$12	+39.7%
Aug 05, 2022	Downgrade	KKeyBanc Capital Markets	Overweight → Sector Weight
Oct 15, 2021	Resumed	CCowen	Outperform	$26	+202.7%
Apr 15, 2021	Initiated	CCanaccord Genuity	Buy	$25	+191.0%
Nov 10, 2020	Initiated	KKeyBanc Capital Markets	Overweight	$32	+272.5%
Oct 08, 2020	Initiated	BBTIG Research	Buy	$18	+109.5%
Jun 02, 2020	Resumed	CCantor Fitzgerald	Overweight	$19 → $20	+132.8%
Oct 14, 2019	Initiated	WWilliam Blair	Outperform
Oct 14, 2019	Initiated	CCowen	Outperform	$17	+97.9%
Oct 14, 2019	Initiated	CCantor Fitzgerald	Overweight	$18	+109.5%

Oct-29-26 09:00AM	Exagen Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-27-26 09:00AM	Exagen to Announce Third Quarter Financial Results on November 10, 2026 (GlobeNewswire)
Aug-04-26 05:03PM	Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability (GuruFocus.com) +37.82%
11:28AM	Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance (InvestorsHub)
08:00AM	Exagen Inc. Reports Second Quarter 2026 Financial Results (GlobeNewswire)
09:00AM	Loading…
Jul-28-26 09:00AM	Exagen Inc. to Participate in Upcoming Investor Conference (GlobeNewswire)
Jul-21-26 09:00AM	Exagen to Announce Second Quarter Financial Results on August 4, 2026 (GlobeNewswire)
Jun-01-26 09:00AM	Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus (GlobeNewswire) +7.43%
May-12-26 03:02AM	Exagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... (GuruFocus.com) -6.78%
May-11-26 10:59AM	Record Revenue Growth and Higher Test Pricing Keep Exagen (XGN) in Focus Despite Ongoing Losses (InvestorsHub) +34.92%
08:00AM	Exagen Inc. Reports First Quarter 2026 Results (GlobeNewswire)
Apr-27-26 09:00AM	Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026 (GlobeNewswire)
Mar-10-26 05:01PM	Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments (GuruFocus.com)
09:20AM	Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
05:35PM	Loading…
Mar-09-26 05:35PM	Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-03-26 09:00AM	Exagen Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-25-26 07:25PM	Agilent Technologies (A) Lags Q1 Earnings and Revenue Estimates (Zacks)
Feb-24-26 09:00AM	Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026 (GlobeNewswire)
Jan-11-26 03:00PM	Exagen Inc. Announces Select Preliminary 2025 Financial Results (GlobeNewswire)
Nov-11-25 09:00AM	Exagen Inc. to Participate in Fourth Quarter Investor Conferences (GlobeNewswire)
Nov-04-25 04:08PM	Exagen Inc (XGN) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansion ... (GuruFocus.com) -8.96%
09:10AM	Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Q3 2025 Results (GlobeNewswire)
Nov-03-25 08:06AM	What To Expect From Exagen Inc (XGN) Q3 2025 Earnings (GuruFocus.com)
Oct-23-25 09:15AM	Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence (GlobeNewswire)
Oct-21-25 04:05PM	Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Aug-12-25 10:30PM	[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Aug-06-25 04:05PM	Exagen Inc. to Participate in Third Quarter Investor Conferences (GlobeNewswire)
Jul-29-25 09:10AM	Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +14.34%
08:00AM	Loading…
08:00AM	Exagen Inc. Reports Strong Q2 2025 Results (GlobeNewswire)
Jul-28-25 09:39AM	Exagen Inc (XGN) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-24-25 09:09AM	Exagen Inc. (XGN): A Bull Case Theory (Insider Monkey)
08:45AM	Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Jul-17-25 04:05PM	Exagen Inc. Appoints Chas McKhann to Board of Directors (GlobeNewswire)
Jul-15-25 04:05PM	Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 (GlobeNewswire)
Jun-23-25 09:00AM	Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics (GlobeNewswire)
May-09-25 04:05PM	Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares (GlobeNewswire) -7.31%
May-08-25 08:30AM	Exagen Inc. Prices Public Offering of Common Stock (GlobeNewswire) -9.81%
May-07-25 04:05PM	Exagen Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +6.39%
May-06-25 03:03AM	Exagen Inc (XGN) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic Wins Amidst ... (GuruFocus.com)
01:18AM	Q1 2025 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 04:51PM	Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:10AM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume (GlobeNewswire)
May-02-25 09:36AM	Exagen Inc (XGN) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-28-25 09:00AM	Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors (GlobeNewswire) +7.09%
Apr-26-25 03:31AM	Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability (Seeking Alpha)
Apr-21-25 04:05PM	Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025 (GlobeNewswire) +9.26%
Mar-12-25 03:04AM	Exagen Inc (XGN) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives (GuruFocus.com)
12:10AM	Q4 2024 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-25 09:15AM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +18.25%
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights (GlobeNewswire)
Feb-25-25 04:05PM	Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025 (GlobeNewswire)
Feb-05-25 06:38AM	Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength? (Zacks) +6.18%
Feb-04-25 04:05PM	Exagen Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire) +29.38%
Jan-12-25 12:00PM	Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results (GlobeNewswire)
Dec-12-24 09:00AM	Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE CTD (GlobeNewswire) +12.02%
Nov-14-24 04:30PM	Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE CTD Platform (GlobeNewswire) +5.45%
Nov-13-24 04:05PM	Exagen Inc. to Participate in Fourth Quarter Investor Conferences (GlobeNewswire)
02:09AM	Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... (GuruFocus.com)
12:51AM	Q3 2024 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 09:25AM	Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.06%
Nov-11-24 07:25AM	Exagen Inc (XGN) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:05PM	Exagen to Announce Third Quarter 2024 Results on November 12, 2024 (GlobeNewswire)
Oct-21-24 04:05PM	Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence (GlobeNewswire)
Sep-04-24 04:05PM	Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire) +15.93%
Aug-29-24 09:55AM	Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now (Zacks)
Aug-26-24 08:50AM	Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Aug-09-24 09:15AM	Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out? (Zacks) +22.46%
Aug-08-24 08:50AM	Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain (Zacks) +12.65%
Aug-05-24 12:53PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +17.65%
09:10AM	Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance (GlobeNewswire)
Aug-02-24 09:00AM	Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-01-24 09:00AM	Exagen Appoints Jeffrey G. Black as New Chief Financial Officer (GlobeNewswire)
Jul-22-24 09:00AM	Exagen to Announce Second Quarter 2024 Results on August 5, 2024 (GlobeNewswire)
Jun-13-24 08:50AM	Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors (Zacks)
May-15-24 05:01AM	Exagen Inc (XGN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Margin ... (GuruFocus.com) +8.52%
May-13-24 12:53PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:10AM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year (GlobeNewswire)
May-06-24 04:05PM	Exagen Announces Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-30-24 04:05PM	Exagen to Announce First Quarter 2024 Results on May 13, 2024 (GlobeNewswire)
Apr-26-24 08:30AM	Exagen Inc. Announces Changes to the Board of Directors (GlobeNewswire)
Mar-19-24 09:37AM	Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript (Insider Monkey) -12.99%
01:55AM	Q4 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-18-24 12:52PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +9.26%
09:25AM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results (GlobeNewswire)
Mar-08-24 09:00AM	Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (GlobeNewswire)
Mar-07-24 04:05PM	Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024 (GlobeNewswire)
Feb-06-24 08:50AM	Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock (Zacks)
Jan-30-24 04:05PM	Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire) -6.52%
Jan-07-24 12:00PM	Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance (GlobeNewswire)
Nov-13-23 04:05PM	Exagen Inc. Reports Strong Third Quarter 2023 Results (GlobeNewswire) +16.44%
Nov-09-23 04:05PM	Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers (GlobeNewswire) -6.25%
Nov-02-23 04:05PM	Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
Oct-30-23 04:05PM	Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023 (GlobeNewswire) +6.75% +6.08%
Sep-28-23 04:05PM	Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chernett Jorey	10% Owner	Oct 19 '26	Buy	7.46	14,000	104,440	2,618,540	Oct 20 08:00 AM
ABALLI JOHN	President and CEO	Oct 16 '26	Sale	7.87	34,294	269,791	805,540	Oct 19 04:52 PM
Black Jeffrey G.	Chief Financial Officer	Sep 01 '26	Sale	7.22	20,614	148,782	323,339	Sep 02 05:39 PM
ABALLI JOHN	President and CEO	Mar 03 '26	Sale	3.62	15,698	56,827	687,299	Mar 04 03:00 PM
ABALLI JOHN	President and CEO	Feb 24 '26	Sale	3.61	11,430	41,262	702,997	Feb 25 07:11 PM
Black Jeffrey G.	Chief Financial Officer	Feb 24 '26	Sale	3.61	1,584	5,718	267,442	Feb 25 07:11 PM

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Executive Chairman of the Board of DirectorsDr. Tina S. Nova Ph.D.

CEOMr. John Aballi

CFO & Corporate SecretaryMr. Jeffrey G. Black

Chief Scientific OfficerDr. Michael Mahler

Vice President of Investor RelationsMs. Tina Jacobsen CFA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XGN

Exagen Inc

Upgrade your Finviz experience